Company intelligence / Profile preview

Jiangsu Sinoyau Biopharmaceutical

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jiangsu Sinoyau Biopharmaceutical is a China-based biotechnology company focused on the research, development, and commercialization of innovative therapies for oncology and other serious diseases. The company maintains a diverse pipeline of small molecule inhibitors and monoclonal antibodies targeting well-validated pathways such as PD-1 and EGFR. Sinoyau aims to address significant unmet medical needs in the Chinese market through both internal R&D and strategic collaborations. Its operations are centered in the Jiangsu province, a major hub for biopharmaceutical innovation in China.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Jiangsu Sinoyau Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Sinoyau Biopharmaceutical.

Explore the full profile